stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Revenue
AbCellera Biologics Inc.'s revenue for fiscal 2025 was $75.1M, up 160.6% from $28.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was $66.2M. Over the past ten years it has ranged from $8.8M (fiscal 2018) to $485.4M (fiscal 2022); the current reading is higher than 63% of that period. AbCellera Biologics Inc. ranks 113th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $75.1M | 160.56% |
| FY2024 | $28.8M | (24.17%) |
| FY2023 | $38.0M | (92.17%) |
| FY2022 | $485.4M | 29.38% |
| FY2021 | $375.2M | 60.92% |
| FY2020 | $233.2M | 1,907.88% |
| FY2019 | $11.6M | 31.49% |
| FY2018 | $8.8M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $4.1M | (51.29%) |
| Mar 2026 | $8.3M | (81.46%) |
| Dec 2025 | $44.9M | 400.88% |
| Sep 2025 | $9.0M | (47.58%) |
| 22 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $1.2B |
| ARQT Arcutis Biotherapeutics, Inc. compare | $508.7M |
| IOVA Iovance Biotherapeutics, Inc. compare | $379.0M |
| ABCL AbCellera Biologics Inc. | $66.2M |
| TNGX Tango Therapeutics, Inc. compare | $62.4M |
| XENE Xenon Pharmaceuticals Inc. compare | $16.9M |
| RLAY Relay Therapeutics, Inc. compare | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | — |
| EWTX Edgewise Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ABCL
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement